Clinical immunotherapy for brain tumors

Neuroimaging Clinics of North America

Volumn 12, Issue 4, 2002, Pages 641-664

  Fecci, Peter E ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211; BACTERIAL TOXIN; BISPECIFIC ANTIBODY; CHLOROQUINE; CYTOKINE; DIPHTHERIA TOXIN; EMD 55900; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT MEL 14 I 131; INTERLEUKIN 2; INTERLEUKIN 4; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 81C6 I 131; MONOCLONAL ANTIBODY BC 2 I 131; MONOCLONAL ANTIBODY BC 4 I 131; PLANT TOXIN; PSEUDOMONAS EXOTOXIN; RADIOISOTOPE; RECOMBINANT PROTEIN; TENASCIN ANTIBODY; TP 38; TRANSFERRIN; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA2; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; Y 10; YTTRIUM 90;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; BRAIN TUMOR; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL MATURATION; CLINICAL TRIAL; DENDRITIC CELL; DOSE CALCULATION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SPECIFICITY; GENE THERAPY; GLIOMA; HUMAN; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SIDE EFFECT;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; DENDRITIC CELLS; GLIOMA; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; IMMUNOTOXINS; MAGNETIC RESONANCE IMAGING; RADIOIMMUNOTHERAPY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036867670     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-5149(02)00027-8     Document Type: Review

References (192)

1. Dropcho EJ. Novel chemotherapeutic approaches to brain tumors. Hematol/Oncol Clin N Am 2001;15:1027-52.
2. Roth W, Weller M. Chemotherapy and immunotherapy of malignant glioma: Molecular mechanisms and clinical perspectives. Cell Mol Life Sci 1999;56:481-506.
3. Giese A, Westphal M. Treatment of malignant glioma: A problem beyond the margins of resection. J Cancer Res Clin Oncol 2001;127:217-25.
4. Dandy WE. Removal of right cerebral hemisphere for certian tumors with hemiplegia. JAMA 1928;90:823-5.
5. Kreth FW, Berlis A, Spiropoulou V, Faist M, Scheremet R, Rossner R, et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 1999;86:2117-23.
6. Kreth FW, Wamke PC, Ostertag CB. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1995;75:2785-7.
7. Quigley MR, Maroon JC. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 1991;29:385-8; discussion 388-9.
8. Walker MD, Green SB, Byar DP, Alexander Jr E, Batzdorf U, Brooks WH, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9.
9. Cokgor I, Friedman HS, Friedman AH. Chemotherapy for adults with malignant glioma. Cancer Invest 1999;17:264-72.
10. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585-97.
11. Stupp R, Dietrich PY, Kraljevic SO, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.
12. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762-71.
13. Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncology 2001;3:246-50.
14. Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long AH, Friedman AH, et al. Phase I trial of carmustine plus O6-benzylgnanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000;18:3522-8.
15. Friedman HS, Lovell S, Rasheed K, Friedman AH. Treatment of adults with progressive oligodendmglioma with carboplatin (CBDCA): Preliminary results. Writing Committee for The Brain Tumor Center at Duke. Med Pediatr Oncol 1998;31:16-8.
16. Kadota RP, Kun LE, Langston JW, Burger PC, Cohen ME, Mahoney DH, et al. Cyclophosphamide for the treatment of progressive low-grade astrocytoma: A Pediatric Oncology Group phase II Study. J Pediatr Hematol Oncol 1999;21:198-202.
17. Graham ML, Herndon II JE, Casey JR, Chaffee S, Ciocci GH, Krischer JP, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997;15:1814-23.
18. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-97.
19. Stewart DJ. The role of chemotherapy in the treatment of gliomas in adults. Cancer Treat Rev 1989;16:129-60.
20. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345:1008-12.
21. Curran Jr WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-10.
22. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
23. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: Studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol 1979;27:51-177.
24. Van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 1982;79:4718-22.
25. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
26. Rosenberg SA, Kawakami Y, Robbins PF, Wang R. Identification of the genes encoding cancer antigens: Implications for cancer immunotherapy. Adv Cancer Res 1996;70:145-77.
27. Miescher S, Whiteside TL, de Tribolet N, von Fliedner V. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 1988;68:438-48.
28. Fine HA. Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Neurol Clin 1995;13:827-46.
29. Medawar PB. Immunity to homologous grafted skin: III - The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948;29:58-69.
30. Parney IF, Hao C, Petruk KC. Glioma immunology and immunotherapy. Neurosurgery 2000;46:778-91; discussion 791-2.
31. Fabry Z, Raine CS, Hart MN. Nervous tissue as an immune compartment: The dialect of the immune response in the CNS. Immunol Today 1994;15:218-24.
32. Cserr HF, Knopf PM. Cervical lymphatics, the bloodbrain barrier and the immunoreactivity of the brain: A new view. Immunol Today 1992;13:507-12.
33. Gehrmann J, Matsumoto Y, Kreutzberg GW. Microglia: Intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 1995;20:269-87.
34. Serot JM, Foliguet B, Bene MC, Faure GC. Ultrastrucrural and immunohistological evidence for dendriticlike cells within human choroid plexus epithelium. Neuroreport 1997;8:1995-8.
35. McMenamin PG, Forrester JV. Dendritic cells in the central nervous system and eye and their associated supporting tissues. In: Thomson AW, editor. Dendritic Cells: Biology and Clinical Applications. New York: Academic Press; 1999. p. 205-48.
36. Owens T, Renno T, Taupin V, Krakowski M. Inflammatory cytokines in the brain: Does the CNS shape immune responses? Immunol Today 1994;15:566-71.
37. Stevens A, Kloter I, Roggendorf W. Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer 1988;61:738-43.
38. Bullard DE, Gillespie GY, Mahaley MS, Bigner DD. Immunobiology of human gliomas. Semin Oncol 1986;13:94-109.
39. Jaeckle KA. Immunotherapy of malignant gliomas. Semin Oncol 1994;21:249-59.
40. Parney IF, Farr-Jones MA, Chang LJ, Petruk KC. Human glioma immunobiology in vitro: Implications for immunogene therapy. Neurosurgery 2000;46:1169-77.
41. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994;54:2218-22.
42. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res 1992;52:1386-92.
43. Zuber P, Kuppner MC, De Tribolet N. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 1988;18:1623-6.
44. Devajyothi C, Kalvakolanu I, Babcock GT, Vasavada HA, Howe PH, Ransohoff RM. Inhibition of interferon-gamma-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocytoma cells. Definition of cis-element. J Biol Chem 1993;268:18794-800.
45. Weller M, Constam DB, Malipiero U, Fontana A. Transforming growth factor-beta 2 induces apoptosis of murine T cell clones without down-regulating bcl2 mRNA expression. Eur J Immunol 1994;24:1293-300.
46. Kawaguchi S, Mineta T, Ichinose M, Masuoka J, Shiraishi T, Tabuchi K. Induction of apoptosis in glioma cells by recombinant human Fas ligand. Neurosurgery 2000;46:431-8; discussion 438-9.
47. Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, et al. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 1997;41:1365-72.
48. Fakhrai H, Mantil J, Gramatikova S, Nicholson G, Murphy-Satter C, Krauss G, et al. Gene therapy of human gliomas with TGF-β2 antisense gene modified autologous tumor cells. A Phase I trial. Proceedings of the American Association for Cancer Research 2000;41:543.
49. Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre JY. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer 1996;32A:636-40.
50. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992;89:2965-9.
51. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
52. Lal A, Sui I, Riggins GJ. Serial analysis of gene expression: Probing transcriptomes for molecular targets. Curr Opin Mol Ther 1999;1:720-6.
53. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J Clin Oncol 1998;16:2202-12.
54. Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA 2000;97:7503-8.
55. Humphrey PA, Wong AJ, Vogelstein B, et al. Antisynthetic peptide antibody reachingn at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 1990;87:4207-11.
56. Wong H, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor gene in malignant gliomas is invariably related with gene amplification. Proc Natl Acad Sci USA 1987;84:6899-903.
57. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, et al. Amplification, enhanced expression and possible rearrangement of the EGF receptor gene in primary human brain tumors of glial origin. Nature 1985;313:144-7.
58. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an antireceptor monoclonal antibody. Proc Natl Acad Sci USA 1983;80:1337-41.
59. Faillot T, Magdelenat H, Mady E, Stasiecki P, Fohanno D, Gropp P, et al. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery 1996;39:478-83.
60. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 1989;49:2807-13.
61. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
62. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7:1204-13.
63. Schober R, Bilzer T, Waha A, Reifenberger G, Wechsler W, von Deimling A, et al. The epidermal growth factor receptor in glioblastoma: Genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin Neuropathol 1995;14:169-74.
64. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N, et al. Amplification of the epidermalgrowth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 1994;56:72-7.
65. Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification - Rearrangement in human glioblastomas. Int J Cancer 1995;62:145-8.
66. Sauter G, Maeda T, Waldman FM, Davis RL, Feuerstein BG. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol 1996;148:1047-53.
67. Bigner SH, Vogelstein B, Bigner DD. Chromosomal abnormalities and gene amplification in malignant gliomas. ISI Atlas of Science: Biochemistry 1988;1:333-6.
68. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990;50:8017-22.
69. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-7.
70. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990;87:8602-6.
71. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 1997;324:855-61.
72. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997;57:4130-40.
73. Leavens ME, Moser RP, Obbens EA, Iwata KI. Surgical treatment of metastatic brain tumors. Cancer Bulletin 1986;38:39-42.
74. Baselga J. Current and planned clinical trials with trastuzumab (Herceptin). Semin Oncol 2000;27:27-32.
75. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 1999;26:71-7.
76. Leyland-Jones B, Smith I. Role of Herceptin in primary breast cancer: Views from North America and Europe. Oncology 2001;61:83-91.
77. Goldenberg MM. Trastuzumab, a recombinant DNAderived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21:309-18.
78. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 2000;27:13-9.
79. Day ED, Lassiter S, Woodhall B, Mahaley JL, Mahaley Jr MS. The localization of radioantibodies in human brain tumors. I. Preliminary exploration. Cancer Res 1965;25:773-8.
80. Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial. Int J Radiat Oncol Biol Phys 1992;22:225-30.
81. Brady LW. A new treatment for high grade gliomas of the brain. Bulletin et Memoires de 1 Academie Royale de Medecine de Belgique 1998;153:255-61; discussion 261-2.
82. Bourdon MA, Wikstrand CJ, Furthmayr H, et al. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 1983;43:2796-805.
83. Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, et al. Intrathecal 13I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin Cancer Res 1996;2:963-72.
84. Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000;18:3862-72.
85. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 1991;115:1127-36.
86. Wikstrand CJ, McLendon RE, Carrel S, Kemshead JT, Mach JP, Coakham HB, et al. Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. J Neuroimmunol 1987;15:37-56.
87. Cokgor I, Akabani G, Friedman HS, Friedman AH, Zalutsky MR, Zehngebot LM, et al. Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab′)(2): A case study. Cancer 2001;91:1809-13.
88. Chamberlain MC. Current concepts in leptomeningeal metastasis. Curr Opin Oncol 1992;4:533-9.
89. Riva P, Arista A, Tison V, Sturiale C, Franceschi G, Spinelli A, et al. Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors. Cancer 1994;73:1076-82.
90. Riva P, Franceschi G, Frattarelli M, Riva N, Guiducci G, Cremonini AM, et al. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma-phase I and II study. Acta Oncologica 1999;38:351-9.
91. Turkington TG, Zalutsky MR, Jaszczak RJ, Garg PK, Vaidyanathan G, Coleman RE. Measuring astatine211 distributions with SPECT. Phys Med Biol 1993;38:1121-30.
92. Zalutsky MR, Cokgor I, Akabani G, Friedman HS, Coleman RE, Friedman AH, et al. Phase I trial of alpha-particle-emitting astatine-211 chimeric anti-tenascin antibody in recurrent malignant glioma patients. Ninety-First Meeting of the American Association of Cancer Research, San Francisco, CA, 2000. Proceedings of the American Association for Cancer Research 2000;41:5448.
93. Hall EJ. Linear energy transfer and relative biological effectiveness. In: Hall EJ, editor. Radiobiology for the Radiologist. 3rd Edition. Philadelphia: Lippincott; 1988, p. 161-77.
94. Kampf G. Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation. Radiobiol Radiother (Berl) 1988;29:631-58.
95. Strickland DK, Vaidyanathan G, Zalutsky MR. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res 1994;54:5414-9.
96. Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncologica 1996;35:373-9.
97. Roeske JC, Chen GTY. A dosimetry model for intracavitary radioimmunotherapy of cystic brain tumors, antibody immunoconjugates. Radiopharmaceuticals 1991;4:637-47.
98. Zalutsky MR, Garg PK, Friedman HS, Bigner DD. Labeling monoclonal antibodies and F(ab′)2 fragments with the alpha-particle-emitting nuclide astatine-211: Preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci USA 1989;86:7149-53.
99. Frankel AE, Tagge EP, Willingham MC. Clinical trials of targeted toxins. Semin Cancer Biol 1995;6:307-17.
100. Hall WA, Fodstad O. Immunotoxins and central nervous system neoplasia. J Neurosurg 1992;76:1-12.
101. Recht L, Tones CO, Smith TW, Raso V, Griffin TW. Transferrin receptor in normal and neoplastic brain tissue: Implications for brain-tumor immunotherapy. J Neurosurg 1990;72:941-5.
102. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TFCRM107 in patients with malignant brain tumors. Nat Med 1997;3:1362-8.
103. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature 1984;312:162-3.
104. Hagihara N, Walbridge S, Olson AW, Oldfield EH, Youle RJ. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res 2000;60:230-4.
105. Leppla S, Dorland RB, Middlebrook JL. Inhibition of diphtheria toxin degradation and cytotoxic action by chloroquine. J Biol Chem 1980;255:2247-50.
106. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6:2157-65.
107. Puri RK, Leland P, Kreitman RJ, Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4Pseudomonas exotoxin chimeric protein. Int J Cancer 1994;58:574-81.
108. Pastan I, Chaudhary V, FitzGerald DJ. Recombinant toxins as novel therapeutic agents. Annu Rev Biochem 1992;61:331-54.
109. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001;92:168-75.
110. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1995;1:1253-8.
111. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999;5:985-90.
112. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL. High-flow microinfusion: Tissue penetration and pharmacodynamics. Am J Physiol 1994;266:R292-305.
113. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;91:2076-80.
114. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995;82:1021-9.
115. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985;314:628-31.
116. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985;316:354-6.
117. Liu MA, Kranz DM, Kumick JT, Boyle LA, Levy R, Eisen HN. Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1985;82:8648-52.
118. Nitta T, Sato K, Yagita H, Okumura K, Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990;335:368-71.
119. Jung G, Brandl M, Eisner W, Fraunberger P, Reifenberger G, Schlegel U, et al. Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: Evidence for in situ T-cell activation and therapeutic efficacy. Int J Cancer 2001;91:225-30.
120. Greenfield L, Johnson VG, Youle RJ. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 1987;238:536-9.
121. LeMay DR, Kittaka M, Gordon EM, Gray B, Stins MF, McComb JG, et al. Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy. Hum Gene Ther 1998;9:989-95.
122. Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, et al. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc Natl Acad Sci USA 1995;92:9829-33.
123. Ford J, Osborn C, Barton T, Bleehen NM. A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer 1998;34:1807-11.
124. Elliott PJ, Hayward NJ, Huff MR, Nagle TL, Black KL, Bartus RT. Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy. Exp Neurol 1996;141:214-24.
125. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:814s-9s.
126. Choucair AK, Levin VA, Gutin PH, Davis RL, Silver P, Edwards MS, et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 1986;65:654-8.
127. Pasquier B, Pasquier D, N'Golet A, Panh MH, Couderc P. Extraneural metastases of astrocytomas and glioblastomas: Clinicopathological study of two cases and review of literature. Cancer 1980;45:112-25.
128. Steinbok P, Thomas JP, Grossman L, Dolman CL. Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme. A phase 1 (toxicity) study. J Neurooncol 1984;2:147-51.
129. Young H, Kaplan A, Regelson W. Immunotherapy with autologous white cell infusions ("lymphocytes") in the treatment of recurrrent glioblastoma multiforme: A preliminary report. Cancer 1977;40:1037-44.
130. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995;76:840-52.
131. Blancher A, Roubinet F, Grancher AS, Tremoulet M, Bonate A, Delisle MB, et al. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. Eur Cytokine Netw 1993;4:331-41.
132. Jacobs SK, Wilson DJ, Komblith PL, Grimm EA. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial. Cancer Res 1986;46:2101-4.
133. Jeffes III EW, Beamer YB, Jacques S, Silberman RS, Vayuvegula B, Gupta S, et al. Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. J Neurooncol 1993;15:141-55.
134. Ingram M, Buckwalter JG, Jacques DB, Freshwater DB, Abts RM, Techy GB, et al. Immunotherapy for recurrent malignant glioma: An interim report on survival. Neurol Res 1990;12:265-73.
135. Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M, et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 1999;45:141-57.
136. Tsurushima H, Liu SQ, Tuboi K, Matsumura A, Yoshii Y, Nose T, et al. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn J Cancer Res 1999;90:536-45.
137. Kitahara T, Watanabe O, Yamaura A, Makino H, Watanabe T, Suzuki G, et al. Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neurooncol 1987;4:329-36.
138. Brooks WH, Markesberry MD, Gupta GF, Roszman TL. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 1978;4:219-24.
139. Palma L, DiLorenzo N, Guidetti B. Lymphocytic infiltrates in primary glioblastomas and recidivious gliomas. J Neurosurg 1978;49:845-61.
140. Grimm EA, Mazumder A, Zhang HC, Rosenberg SA. Lymphokine activated killer cell phenomenon lysis of natural killer cell-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-41.
141. Lotze MT, Matory YL, Ettinghausln SE, Raynor AA, Sharrow SO, Seipp CA, et al. In vivo administration of purified human interleukin-2. II. Half-life, immunological effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 1985;135:2865-75.
142. Riva P, Franceschi G, Frattarelli M, Lazzari S, Riva N, Giuliani G, et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: A phase I study. Clin Cancer Res 1999;5:3275s-80s.
143. Lampson LA, Hickey WF. Monoclonal antibody analysis of MHC expression in human brain biopsies: Tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J Immunol 1986;136:4054-62.
144. Lampson LA. Interpreting MHC class I expression and class I/class II reciprocity in the CNS: Reconciling divergent findings. Microsc Res Tech 1995;32:267-85.
145. Bigner DD, Bigner SH, Ponten J, Westermark B, Mahaley MS, Ruoslahti E, et al. Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 1981;40:201-29.
146. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Franklin WA, Morse HG, Spector EB, et al. Characterization of a continuous human glioma cell line DBTRG-05MG: Growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses. In Vitro Cell Dev Biol Anim 1992;28A:609-14.
147. Whelan JP, Chatten J, Lampson LA. HLA class I and beta 2-microglobulin expression in frozen and formaldehyde-fixed paraffin sections of neuroblastoma tumors. Cancer Res 1985;45:5976-83.
148. Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, Ferrone S. Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res 1984;44:4679-87.
149. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 1997;45:77-87.
150. Virasch N, Kruse CA. Strategies using the immune system for therapy of brain tumors. Hematol/Oncol Clin N Am 2001;15:1053-71.
151. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
152. Hosli P, Sappino AP, de Tribolet N, Dietrich PY. Malignant glioma: Should chemotherapy be overthrown by experimental treatments? Ann Oncol 1998;9:589-600.
153. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA 1996;93:10399-404.
154. Wood GW, Turner T, Wang YY, Holladay FP. Immune rejection of intracerebral gliomas using lymphocytes from glioma-bearing rats. J Immunother 1999;22:497-505.
155. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61:842-7.
156. Mahaley Jr MS, Bigner DD, Dudka LF, Wilds PR, Williams DH, Bouldin TW, et al. Immunobiology of primary intracranial tumors. Part 7. Active immunization of patients with anaplastic human glioma cells: A pilot study. J Neurosurg 1983;59:201-7.
157. Holladay FP, Heitz-Turner T, Bayer WL, Wood GW. Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. J Neurooncol 1996;27:179-89.
158. Wood GW, Holladay FP, Turner T, Wang YY, Chiga M. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol 2000;48:113-20.
159. Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998;89:42-51.
160. Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000;6:2209-18.
161. Glick RP, Lichtor T, de Zoeten E, Deshmukh P, Cohen EP. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery 1999;45:867-74.
162. Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, et al. Cytokine gene therapy of gliomas: Induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 2000;60:2449-57.
163. Okada H, Villa L, Attanucci J, Erff M, Fellows WK, Lotze MT, et al. Cytokine gene therapy of gliomas: Effective induction of therapeutic immunity
164. Yu JS, Burwick JA, Dranoff G, Breakefield XO. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 1997;8:1065-72.
165. Natsume A, Mizuno M, Ryuke Y, Yoshida J. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther 1999;6:1626-33.
166. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
167. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
168. Sobol RE, Fakhrai H, Shawler DL, Gjerset R, Dorigo O, Carson C, et al. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 1995;2:164-7.
169. Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, Lieberman F, et al. Gene therapy of malignant gliomas: A phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 2000;11:637-53.
170. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
171. Grabbe S, Beissert S, Schwarz T, Granstein RD. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol Today 1995;16:117-21.
172. Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 1989;63:496-503.
173. Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimachi K. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 1990;66:2012-6.
174. Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 2002;50:158-64.
175. Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 2000;103:16-25.
176. Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, et al. Bone marrowderived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 1998;78:196-201.
177. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177-82.
178. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999;90:1115-24.
179. Ni HT, Spellman SR, Jean WC, Hall WA, Low WC. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 2001;51:1-9.
180. Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 2001;94:474-81.
181. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59:56-8.
182. Barratt-Boyes SM, Zimmer MI, Harshyne LA, Meyer EM, Watkins SC, Capuano III S, et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: Implications for dendritic cell-based vaccines. J Immunol 2000;164:2487-95.
183. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001;166:4254-9.
184. elu. Proceedings of the American Association for Cancer Research. San Francisco, April 6-10, 2002.
185. Sloan AE, Parajuli P, Mathupala S. DC-tumor cell fusion for induction of tumor-specific T-cell response against malignant brain tumors: Comparison with DC pulsed with total tumor RNA or tumor lysate. In: Proceedings of the American Association for Cancer Research. San Francisco, April 6-10, 2002.
186. Binder RJ, Han DK, Srivastava PK. CD91: A receptor for heat shock protein gp96. Nat Immunol 2000;1:151-5.
187. Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 2000;106:1065-9.
188. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-72.
189. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332-6.
190. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cellderived exosomes. Nat Med 1998;4:594-600.
191. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999;147:599-610.
192. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001;7:297-303.